GSK to provide adjuvant to boost effectiveness, stretch supplies of 2019-nCoV vaccines

GlaxoSmithKline will provide its AS03 adjuvant technology to enhance 2019-nCoV vaccines that are being funded by the Coalition for Epidemic Preparedness Innovations, GSK and CEPI announced Sunday.

AS03

Read the full 285 word article

How to gain access

Continue reading with a
two-week free trial.